Acalabrutinib
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Food Allergy
Conditions
Food Allergy, Food Allergy Peanut
Trial Timeline
Dec 16, 2021 → Dec 31, 2022
NCT ID
NCT05038904About Acalabrutinib
Acalabrutinib is a phase 2 stage product being developed by AstraZeneca for Food Allergy. The current trial status is completed. This product is registered under clinical trial identifier NCT05038904. Target conditions include Food Allergy, Food Allergy Peanut.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (15)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06757647 | Phase 2 | Recruiting |
| NCT06651970 | Approved | Recruiting |
| NCT06205498 | Pre-clinical | Active |
| NCT05256641 | Phase 1/2 | Recruiting |
| NCT05557695 | Pre-clinical | Recruiting |
| NCT04660045 | Phase 2 | Withdrawn |
| NCT05038904 | Phase 2 | Completed |
| NCT04198922 | Phase 2 | Active |
| NCT04548648 | Phase 2 | Active |
| NCT04497948 | Phase 1 | Terminated |
| NCT04380688 | Phase 2 | Completed |
| NCT04346199 | Phase 2 | Completed |
| NCT03932331 | Phase 1/2 | Active |
| NCT04008706 | Phase 3 | Completed |
| NCT03968848 | Phase 1 | Completed |
Competing Products
17 competing products in Food Allergy